Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Nvidia Corp — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $5.22 (market cap $1.74B), while Nvidia Corp trades at $233.92 (market cap $5.57T). The key difference: Nvidia Corp is far larger — about 3201.1× Nuvation Bio Inc. Class A Common Stock's market cap, and Nvidia Corp pays a 0.43% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Nvidia Corp for 115 Days on average.
| NUVB | NVDA | |
|---|---|---|
Market Cap | $1.74B | $5.57T |
Volume | 9,289,619 | 117,720,595 |
Sector | Health | Technology |
52-Week High | $9.54 | $239.27 |
52-Week Low | $3.41 | $165.17 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $1.33B | $5.54T |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NVIDIA (NVDA) trades at $237.36, down 0.8% on the day, amid strong fundamental performance with revenue surging to $130.5 billion in 2025 and net income reaching $72.88 billion. The stock maintains a bullish technical outlook with moving averages signaling strength, though RSI levels suggest potential overbought conditions. Recent earnings beats and a 75.95% analyst buy rating support positive sentiment, while the company's dominant position in AI chips drives continued growth expectations.
Outlook remains positive with a consensus price target of $339.17 representing significant upside potential. Key opportunities include sustained AI demand and expanding market leadership, while risks involve increased competition, peak AI spending concerns, and valuation metrics above industry averages. The stock's current valuation reflects high growth expectations that must be met to justify further appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
